^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial
Published date:
05/26/2022
Excerpt:
The Short-HER study randomized 1254 patients with HER2+ early breast cancer to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with anthracycline-taxane chemotherapy. 853 patients with HR+ BC (ER and/or PgR >10%) were included…patients who received AI had a significantly better DFS as compared to patients who received TAM or TAM-AI: 7-yr DFS 87.3% vs 81.7%, log-rank P=0.017 (HR 1.46, 95%CI 1.05-2.03).
Secondary therapy:
Aromatase inhibitor; Chemotherapy
DOI:
10.1200/JCO.2022.40.16_suppl.547
Trial ID:
Source:
Title:
HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
Published date:
10/14/2020
Excerpt:
...1306 cases were included in the present analysis....ER+/HER2+ patients treated with trastuzumab and chemotherapy (HER2-pos-T group) and ER+/HER2-patients treated with chemotherapy alone (HER2-neg group) were included for the further analysis….The estimated 5-year OS rates were 95.7% and 97.2% in the HER2-neg group and the HER2-pos-T group, respectively....More importantly, ER+/HER2+ patients treated with trastuzumab and chemotherapy had superior disease outcome compared with ER+/HER2-patients, indicating that HER2 positivity itself may not be considered as a risk factor for ER + patients in the era of trastuzumab, which warrants further clinical investigation.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.breast.2020.10.002
Source:
Title:
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
A multicenter, prospective clinical study of darceline combined with trastuzumab+pyrroltinib+letrozole in the treatment of ER+/HER2+ early breast cancer
Excerpt:
...ER positive was defined as: the proportion of tumor cells with positive staining accounted for more than 10% of all tumor cells (reviewed and confirmed by investigators in the study center); HER2 positive definition: IHC 3+ or IHC2+ but ISH positive (reviewed and confirmed by the investigator at the study center). ...
Trial ID:
More C2 evidence
Source:
Title:
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Excerpt:
...- Estrogen receptor-positive and/or progesterone receptor-positive disease...
Trial ID:
Source:
Title:
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
Excerpt:
...- Estrogen receptor-positive patients on hormone replacement therapy (HRT) must either continue HRT or must...
Trial ID:
Source:
Title:
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
Excerpt:
...- Estrogen receptor positive tumor...
Trial ID:
Source:
Title:
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Excerpt:
...Both estrogen receptor (ER)-positive/HER2-positive and ER-negative/HER2-positive will be eligible....
Trial ID:
Source:
Title:
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Excerpt:
...- Part A: Triple-negative disease (ER/PR/HER2-negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting; or ER-positive and/or PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are...
Trial ID:
Source:
Title:
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Excerpt:
...- ER-positive and/or PR-positive disease...
Trial ID:
Less C2 evidence
Source:
Title:
Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
Published date:
07/13/2021
Excerpt:
The estimated 5-year DFS rate was 89.7% in the HER2-neg group and 90.2% in the HER2-pos-T group (P = 0.185), respectively. Multivariable analysis demonstrated that patients in the HER2-pos-T group had a better DFS than patients in the HER2-neg group (HR 0.52, 95% CI: 0.37-0.73, P < 0.001). The estimated 5-year OS rates were 96.0% and 96.3% in the two groups, respectively (P = 0.133). Multivariate analysis found that HER2-pos-T group was still associated with significantly better OS compared with the HER2-neg group (HR 0.38, 95% CI: 0.22-0.67, P = 0.037). ER+/HER2+ breast cancer patients treated with trastuzumab were associated with superior outcome compared with ER+/HER2- patients...
DOI:
10.1186/s12885-021-08555-4
Source:
Title:
Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
Published date:
02/12/2021
Excerpt:
Female patients with LABC (T2-T4, N0-N2, and M0) who received neoadjuvant chemotherapy + trastuzumab….At median follow-up of 61 months, ER+/HER2+ and ER+/HER2- subtypes had the best 5-year DFS and OS; meanwhile, ER-/HER2+ and ER-/HER2- subtypes had the worst.
Secondary therapy:
Chemotherapy
DOI:
10.1155/2021/6639763
